Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ludvigsson M. L.) "

Sökning: WFRF:(Ludvigsson M. L.)

  • Resultat 21-30 av 59
  • Föregående 12[3]456Nästa
Sortera/gruppera träfflistan
  • Ludvigsson, J. F., et al. (författare)
  • Swedish Inflammatory Bowel Disease Register (SWIBREG)–a nationwide quality register
  • 2019
  • Ingår i: Scandinavian Journal of Gastroenterology. - Taylor & Francis. - 0036-5521. ; 54:9, s. 1089-1101
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Inflammatory bowel disease (IBD) is a chronic, inflammatory relapsing disease with increasing incidence. IBD research and long-term follow-up of patients have, however, been hampered by lack of detailed data on disease phenotype, patient-reported outcome measures, Physician Global Assessment, disease activity, and hospital-administered drugs.Aim: To review the Swedish IBD quality register (SWIBREG).Methods: Review of SWIBREG including questionnaire data from users and patients.Results: SWIBREG was launched in 2005, and as of April 2019, contains 46,400 patients with IBD (Crohn’s disease: n = 15,705, ulcerative colitis: n = 21,540, IBD unclassified and other colitis (including e.g., microscopic colitis): n = 9155). Of these IBD patients, 7778 had been diagnosed in childhood (16.8%). Earlier research has shown that combining SWIBREG and the Swedish National Patient Register (NPR) yields a positive predictive value of 100% (95%CI = 95–100%) for having a diagnosis of IBD. Moreover, out of all patients in the NPR with a diagnosis of IBD plus either IBD-related surgery or immunomodulatory/biological treatment during the past 18 months, SWIBREG covers 59.0%. SWIBREG records not only information on conventional therapies but also on biological treatment, surgery, smoking, disease activity, patient-reported outcome measures (PROMs), and patient-experienced measures (PREMs). Data are presented through a graphical decision support system.Conclusion: SWIBREG benefits patients with IBD, and offers an ideal opportunity for healthcare personnel and researchers to examine disease phenotype and activity, PROMs/PREMs, and hospital-administered drugs in patients with IBD. 
  • Nucci, Anita M, et al. (författare)
  • Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial.
  • 2016
  • Ingår i: Maternal and Child Nutrition. - 1740-8695.
  • Tidskriftsartikel (refereegranskat)abstract
    • Differences in breastfeeding, other milk feeding and complementary feeding patterns were evaluated in infants at increased genetic risk with and without maternal type 1 diabetes (T1D). The Trial to Reduce IDDM in the Genetically at Risk is an international nutritional primary prevention double-blinded randomized trial to test whether weaning to extensively hydrolyzed vs. intact cow's milk protein formula will decrease the development of T1D-associated autoantibodies and T1D. Infant diet was prospectively assessed at two visits and seven telephone interviews between birth and 8 months. Countries were grouped into seven regions: Australia, Canada, Northern Europe, Southern Europe, Central Europe I, Central Europe II and the United States. Newborn infants with a first-degree relative with T1D and increased human leukocyte antigen-conferred susceptibility to T1D were recruited. A lower proportion of infants born to mothers with than without T1D were breastfed until 6 months of age in all regions (range, 51% to 60% vs. 70% to 80%). Complementary feeding patterns differed more by region than by maternal T1D. In Northern Europe, a higher proportion of infants consumed vegetables and fruits daily compared with other regions. Consumption of meat was more frequent in all European regions, whereas cereal consumption was most frequent in Southern Europe, Canada and the United States. Maternal T1D status was associated with breastfeeding and other milk feeding patterns similarly across regions but was unrelated to the introduction of complementary foods. Infant feeding patterns differed significantly among regions and were largely inconsistent with current recommended guidelines.
  • Sundström, Johan, et al. (författare)
  • Rationale for a Swedish cohort consortium
  • 2019
  • Ingår i: Upsala Journal of Medical Sciences. - TAYLOR & FRANCIS LTD. - 0300-9734 .- 2000-1967. ; 124:1, s. 21-28
  • Tidskriftsartikel (refereegranskat)abstract
    • We herein outline the rationale for a Swedish cohort consortium, aiming to facilitate greater use of Swedish cohorts for world-class research. Coordination of all Swedish prospective population-based cohorts in a common infrastructure would enable more precise research findings and facilitate research on rare exposures and outcomes, leading to better utilization of study participants' data, better return of funders' investments, and higher benefit to patients and populations. We motivate the proposed infrastructure partly by lessons learned from a pilot study encompassing data from 21 cohorts. We envisage a standing Swedish cohort consortium that would drive development of epidemiological research methods and strengthen the Swedish as well as international epidemiological competence, community, and competitiveness.
  • Knip, Mikael, et al. (författare)
  • Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes The TRIGR Randomized Clinical Trial
  • 2018
  • Ingår i: Journal of the American Medical Association (JAMA). - AMER MEDICAL ASSOC. - 0098-7484. ; 319:1, s. 38-48
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cows milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. MAIN OUTCOMES AND MEASURES Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (n = 91) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8%[95% CI, -1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes.
  • Lahdenperä, Anna, et al. (författare)
  • Up-regulation of small intestinal interleukin-17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes
  • 2012
  • Ingår i: Clinical and Experimental Immunology. - John Wiley & Sons. - 0009-9104. ; 167:2, s. 226-234
  • Tidskriftsartikel (refereegranskat)abstract
    • Up-regulation of interleukin (IL)-17 in small intestinal mucosa has been reported in coeliac disease (CD) and in peripheral blood in type 1 diabetes (T1D). We explored mucosal IL-17 immunity in different stages of CD, including transglutaminase antibody (TGA)-positive children with potential CD, children with untreated and gluten-free diet-treated CD and in children with T1D. Immunohistochemistry was used for identification of IL-17 and forkhead box protein 3 (FoxP3)-positive cells and quantitative polymerase chain reaction (qPCR) for IL-17, FoxP3, retinoic acid-related orphan receptor (ROR)c and interferon (IFN)-γ transcripts. IL-1β, IL-6 and IL-17 were studied in supernatants from biopsy cultures. Expression of the apoptotic markers BAX and bcl-2 was evaluated in IL-17-stimulated CaCo-2 cells. The mucosal expression of IL-17 and FoxP3 transcripts were elevated in individuals with untreated CD when compared with the TGA-negative reference children, children with potential CD or gluten-free diet-treated children with CD (P andlt; 0·005 for all IL-17 comparisons and P andlt; 0·01 for all FoxP3 comparisons). The numbers of IL-17-positive cells were higher in lamina propria in children with CD than in children with T1D (P andlt; 0·05). In biopsy specimens from patients with untreated CD, enhanced spontaneous secretion of IL-1β, IL-6 and IL-17 was seen. Activation of anti-apoptotic bcl-2 in IL-17-treated CaCo-2 epithelial cells suggests that IL-17 might be involved in mucosal protection. Up-regulation of IL-17 could, however, serve as a biomarker for the development of villous atrophy and active CD.
  • Landegren, N, et al. (författare)
  • AIREing out autoimmunity
  • 2015
  • Ingår i: SCIENCE TRANSLATIONAL MEDICINE. - 1946-6234. ; 7:292
  • Tidskriftsartikel (övrigt vetenskapligt)
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 59
  • Föregående 12[3]456Nästa
fritt online (14)
Typ av publikation
tidskriftsartikel (53)
konferensbidrag (6)
Typ av innehåll
refereegranskat (51)
övrigt vetenskapligt (9)
Ludvigsson, J, (16)
Ludvigsson, Johnny, (11)
Lindblad, B, (9)
Forsander, G, (9)
Aman, J (8)
visa fler...
Neiderud, J, (8)
Johansson, C., (7)
Kockum, K (7)
Holmberg, E. (7)
Westphal, O (7)
Carlsson, E. (7)
Thalme, B (7)
Gustavsson, I (7)
Ludvigsson, JF, (6)
Tuvemo, T (6)
Ludvigsson, Jonas F. ... (6)
Hanas, R. (6)
Sjöblad, S (6)
Kockum, I. (5)
Ekbom, A (5)
Lernmark, Åke, (5)
Hanås, R (5)
Ivarsson, Sten A. (5)
Larsson, H (4)
Landin-Olsson, Mona, (4)
Landén Ludvigsson, M ... (4)
Pedersen, L (4)
Dahlquist, G (4)
Graham, J (3)
Peolsson, A (3)
Hammarstrom, L, (3)
Emilsson, L (3)
Halfvarson, Jonas, 1 ... (3)
Scherstén, Bengt, (3)
Lernmark, Å (3)
Ivarsson, S-A (3)
Ludvigsson, M. L., (3)
Peterson, G., (3)
Tuvemo, Torsten, (3)
Marcus, C, (3)
Virtanen, Suvi M (3)
Ludvigsson, Johnny, ... (3)
Savilahti, Erkki (3)
Olen, O, (3)
Olen, Ola (3)
Knip, Mikael, (3)
McNeney, B (3)
Messing, M. E. (3)
visa färre...
Linköpings universitet (25)
Karolinska Institutet (25)
Lunds universitet (16)
Uppsala universitet (15)
Örebro universitet (10)
Göteborgs universitet (8)
visa fler...
Mälardalens högskola (3)
Umeå universitet (2)
Högskolan i Jönköping (2)
Stockholms universitet (1)
RISE (1)
visa färre...
Engelska (58)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (42)
Naturvetenskap (3)
Teknik (2)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy